The news offers a tailwind ? if only temporarily ? to a biotech sector that has suffered over the last quarter, and more specifically, to gene therapy developers plagued by high-profile failures in 2015.

from Forbes – Tech http://ift.tt/1Q18E9V
via IFTTT